Treatment with EZH2 and DNMT1 epigenetic regulators synergistically loosened Th1‐type chemokine repression and promoted effector T‐cell tumor trafficking; thus, ultimately potentiating the therapeutic effect of programmed death‐ligand 1 (PD‐L1) and adoptive T‐cell transfusion.[81]. Here, EZH2 is linked to neoplasm.